T1081
TLQP-21 human
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.32
UNSPSC Code:
12352200
form
lyophilized powder
Quality Level
color
white
solubility
deionized water: soluble
shipped in
dry ice
storage temp.
−20°C
General description
TLQP-21 peptide is a derivative of VGF and is expressed at higher levels in the brain.
Biochem/physiol Actions
TLQP-21 peptide is involved in the central and peripheral nervous system activities such as regulating reproductive and circadian behaviors, feeding, and body weight. It is also involved in regulating neuropathic pain and peripheral adiposity. TLQP-21 plays a role in stimulating the secretion of insulin and prevents apoptosis of pancreatic cells. It also activates the complement C3a receptor-1 (C3aR1) in the brain.
Physical form
Lyophilized from 0.1% aqueous TFA
Other Notes
Lyophilized from 0.1% TFA in H2O
Storage Class
11 - Combustible Solids
wgk
WGK 3
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Wei Zhang et al.
PloS one, 8(11), e79760-e79760 (2013-11-28)
Hyperglycemia causes oxidative stress that could damage vascular endothelial cells, leading to cardiovascular complications. The Vgf gene was identified as a nerve growth factor-responsive gene, and its protein product, VGF, is characterized by the presence of partially cleaved products. One
A Bartolomucci et al.
Proceedings of the National Academy of Sciences of the United States of America, 103(39), 14584-14589 (2006-09-20)
The vgf gene has been identified as an energy homeostasis regulator. Vgf encodes a 617-aa precursor protein that is processed to yield an incompletely characterized panel of neuropeptides. Until now, it was an unproved assumption that VGF-derived peptides could regulate
Farida El Gaamouch et al.
Molecular neurodegeneration, 15(1), 4-4 (2020-01-12)
Multiomic studies by several groups in the NIH Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD) identified VGF as a major driver of Alzheimer's disease (AD), also finding that reduced VGF levels correlate with mean amyloid plaque density, Clinical Dementia Rating
Global Trade Item Number
| SKU | GTIN |
|---|---|
| T1081-0.5MG | 04061832677958 |
| T1081-1MG | 04061826153390 |